Proactive: Race Oncology advances RNA epigenetics with FTO drug discovery at Monash

Race CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP).

Watch the full interview below and for the full news report via this link.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@raceoncology.com T: +61 2 8051 3043
© 2025 Race Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Race Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.